ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.70
      0.13%
      US Tech 100
      17,617.63
      0.04%
      Dow Jones
      38,884.26
      0.08%
      Brent Oil
      82.715
      -0.18%
      Bitcoin
      62,547.23
      0.34%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. Biohaven Ltd (BHVN)

      7. Biohaven Ltd (BHVN) News

      BHVN

      Biohaven (BHVN)

      Biohaven Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:BHVN
      DateTimeSourceHeadlineSymbolCompany
      12:51PMiHub NewswireFeaturedCannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa
      04/22/20244:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
      04/17/20244:05PMPR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
      04/13/20249:00AMPR Newswire (US)Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business UpdatesNYSE:BHVNBiohaven Ltd
      02/29/20244:16PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      02/29/20244:05PMPR Newswire (US)Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
      01/08/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      01/08/20247:30AMPR Newswire (US)Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncoloNYSE:BHVNBiohaven Ltd
      01/02/20247:00AMPR Newswire (US)Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
      12/01/20234:30PMPR Newswire (US)Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingNYSE:BHVNBiohaven Ltd
      11/14/20234:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
      11/14/20234:05PMPR Newswire (US)Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
      10/16/20237:00AMPR Newswire (US)Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®NYSE:BHVNBiohaven Ltd
      10/05/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      10/05/20234:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
      10/04/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
      10/02/202311:56PMPR Newswire (US)Biohaven Announces Pricing of $225 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
      10/02/20239:41PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      10/02/20235:09PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
      10/02/20235:07PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
      10/02/20234:36PMPR Newswire (US)BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARESNYSE:BHVNBiohaven Ltd
      10/02/20234:01PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:BHVNBiohaven Ltd
      09/27/20236:58AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      09/14/20237:00AMPR Newswire (US)Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular AtrophyNYSE:BHVNBiohaven Ltd
      09/05/20237:00AMPR Newswire (US)Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal StudiesNYSE:BHVNBiohaven Ltd
      07/31/20235:18PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
      07/31/20234:29PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
      07/31/20239:31AMPR Newswire (US)Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular AtrophyNYSE:BHVNBiohaven Ltd
      07/31/20236:59AMPR Newswire (US)Biohaven Reports Second Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
      07/28/20234:35PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
       Showing the most relevant articles for your search:NYSE:BHVN